A risk scoring system to predict the risk of new‐onset hypertension among patients with type 2 diabetes. Issue 8 (12th July 2021)

• Record Type: Journal Article
• Authors: Lin, Cheng‐Chieh; Li, Chia‐Ing; Liu, Chiu‐Shong; Lin, Chih‐Hsueh; Wang, Mu‐Cyun; Yang, Shing‐Yu; Li, Tsai‐Chung
• Is Part Of: Journal of clinical hypertension. Volume 23:Issue 8(2021)
• Page Start: 1570
• Page End: 1580
• Publication Date: 2021-07-12
• Subjects: hypertension -- risk scoring system -- type 2 diabetes; Hypertension -- Periodicals; 616.132
• DOI: 10.1111/jch.14322
• Languages: English
• ISSNs: 1524-6175

Abstract

Abstract: Hypertension (HTN), which frequently co‐exists with diabetes mellitus, is the leading major cause of cardiovascular disease and death globally. This study aimed to develop and validate a risk scoring system considering the effects of glycemic and blood pressure (BP) variabilities to predict HTN incidence in patients with type 2 diabetes. This research is a retrospective cohort study that included 3416 patients with type 2 diabetes without HTN and who were enrolled in a managed care program in 2001–2015. The patients were followed up until April 2016, new‐onset HTN event, or death. HTN was defined as diastolic BP (DBP) ≥ 90 mm Hg, systolic BP (SBP) ≥ 140 mm Hg, or the initiation of antihypertensive medication. Cox proportional hazard regression model was used to develop the risk scoring system for HTN. Of the patients, 1738 experienced new‐onset HTN during an average follow‐up period of 3.40 years. Age, sex, physical activity, body mass index, type of DM treatment, family history of HTN, baseline SBP and DBP, variabilities of fasting plasma glucose, SBP, and DBP and macroalbuminuria were significant variables for the prediction of new‐onset HTN. Using these predictors, the prediction models for 1‐, 3‐, and 5‐year periods demonstrated good discrimination, with AUC values of 0.70–0.76. Our HTN scoring system for patients with type 2 DM, which involves innovative predictors of glycemic and BP variabilities, has good classification accuracy and identifies risk factors available in clinical settings for prevention of the progression to new‐onset HTN.